Vera Therapeutics (NASDAQ:VERA) saw its shares rise 7.05% to $42.96 on Tuesday after the U.S. Food and Drug Administration granted accelerated approval to Trutakna, a novel therapy for primary IgA nephropathy. The approval, which came ahead of the July 7 PDUFA date, marks a significant milestone for the biotech firm, though investor attention is already shifting to upcoming Phase 3 data expected in the third quarter of 2026.
Tuesday's session saw approximately 4.43 million shares change hands, roughly 2.6 times the average daily volume of 1.68 million shares. The move added about $203 million in equity value, equivalent to roughly 34% of Vera's last reported cash balance of $596.8 million as of March 31, 2026. Despite the pop, the stock remains about 23% below its 52-week high of $56.04 but has surged 125% from its 52-week low of $19.07.
Trutakna's Approval and Mechanism
The FDA cleared Trutakna as a once-weekly subcutaneous injection to reduce proteinuria in adults with primary IgA nephropathy who are at risk of disease progression. The drug is the first approved therapy targeting both BAFF and APRIL, two immune proteins linked to abnormal IgA antibody levels. This dual mechanism sets it apart from existing treatments, but the FDA noted that Trutakna's impact on slowing kidney function decline has not yet been proven. Full approval will likely depend on results from the ongoing ORIGIN 3 trial.
Vera reported that interim data from ORIGIN 3 showed Trutakna reduced proteinuria by 46% from baseline and by 42% versus placebo at 36 weeks. Common side effects included infections and local administration reactions. The trial remains blinded and uses a placebo control, with estimated glomerular filtration rate (eGFR) data due in Q3 2026.
CEO Marshall Fordyce stated in the approval announcement, "We believe TRUTAKNA offers a novel approach to addressing this serious disease." Richard Lafayette, lead investigator of the ORIGIN program and a nephrologist at Stanford, emphasized that Trutakna "inhibits both BAFF and APRIL, the two key cytokines that act on B cells." Fordyce also told Reuters that the company pushed for faster kidney-function checks, as high-risk patients cannot afford to wait years for data.
Analyst Sentiment and Competition
Wall Street remains largely bullish on Vera. Out of 13 analysts tracked over the past three months, 12 rate the stock a buy and one a hold. BofA Securities' Dina Ramadane reiterated a buy rating and $70 price target on July 7. H.C. Wainwright's Arthur He maintained a buy rating and $110 target on July 1. The average analyst target stands at $80.55, implying 87.5% upside from Tuesday's close, while the lowest target is $35.00.
Trutakna enters a competitive landscape. Existing IgA nephropathy therapies include Otsuka Holdings' Voyxact, Novartis' Fabhalta, Travere Therapeutics' Filspari, and Calliditas Therapeutics' Tarpeyo. Vera will need to differentiate Trutakna on efficacy and safety to capture market share.
Financial Position and Outlook
Vera's spending has increased ahead of the launch. The company reported a net loss of $121.0 million for the first quarter of 2026, up from $51.7 million a year earlier. Research and development expenses jumped to $86.0 million from $41.3 million, while general and administrative costs rose to $39.1 million from $15.9 million. As of March 31, Vera held $596.8 million in cash, equivalents, and marketable securities, which management believes will fund operations through approval, a U.S. launch, and additional runway. With the approval now secured, the focus turns to commercial execution and the critical eGFR data due in Q3.
Tuesday's gain, while notable, represents only a fraction of Vera's $3.08 billion market capitalization. The stock's modest move suggests investors are pricing in both the approval and the uncertainty surrounding the ORIGIN 3 readout. The next few months will be pivotal as the company transitions from regulatory risk to launch risk, with the real test being whether Trutakna can demonstrate a clear benefit on kidney function.
